Peripheral/Endo

Shockwave Medical Shows Off Disrupt BTK Lithoplasty System Study Results

FREMONT, Calif.–(BUSINESS WIRE)–Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today reported positive results from the DISRUPT BTK Study, which were presented at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress in Copenhagen, Denmark. DISRUPT BTK, a prospective single arm study, evaluated the use […]

iVascular EffPAC 6 Months Outstanding Data Presented at CIRSE 2017 DCB Session

By Anastasia Perebeynos Copenhagen – September 18, 2017 – iVascular SLU data announced today, demonstrate the efficacy of the Luminor drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The 6 months results from the full clinical cohort of the EffPAC randomized study were presented in the DCB session at the […]

Meta-Analysis Shows RenalGuard(R) Offers Dramatic Benefit for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Cardiovascular Interventions

MILFORD, MA–(Marketwired – September 13, 2017) – A new meta-analysis suggests that the use of the RenalGuard System® reduces the rate of contrast-induced acute kidney injury (CI-AKI) compared to standard intravascular volume expansion in moderate-to-high-risk patients with chronic kidney disease who are undergoing cardiac interventional procedures. The study, published in the Journal […]

SurModics (SRDX) Nabs Global Approvals of .014″ Low-Profile PTA Balloon Dilation Catheter

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) and CE Mark clearance for its .014” low-profile percutaneous transluminal angioplasty (PTA) balloon dilation catheter, designed for […]

Efficacy Of Royal Philips Electronics N.V. (PHG)’ Stellarex .035″ Low-Dose Drug-Coated Balloon Demonstrated In Clinical Trial At Two Years

AMSTERDAM and LAS VEGAS, Sept. 14, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating the efficacy of Philips Spectranetics’ Stellarex .035″ drug-coated balloon (DCB) for peripheral arterial disease (PAD) in comparison to uncoated balloon angioplasty. Marianne […]

Medtronic (MDT) Shows Off New 5-Year Subset Data From Endurant AAA Stent Graft Trial

DUBLIN and LAS VEGAS – September 13, 2017 – Medtronic plc (NYSE: MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting among both male and female patients. The five-year ENGAGE global registry data were presented […]

Six-Month Data From The SurModics (SRDX) Surveil Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2017

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company’s SurVeil®drug-coated balloon (DCB) was shared in a late-breaking clinical trial presentation at the Vascular Interventional Advances (VIVA) 2017 […]

Lombard Medical Announces Completion of Restructuring and Implementation of Strategic Plan to Achieve Profitability

OXFORDSHIRE, England–(BUSINESS WIRE)–Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced completion of a restructuring following the implementation of its new strategy to focus sales efforts in the UK, Japan and China, and reduce operating and manufacturing costs in order to […]

First Round Of Late-Breaking Endovascular Clinical Trial Results Announced At VIVA 17

LAS VEGAS, Sept. 12, 2017 /PRNewswire-USNewswire/ — VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the first five of 20 highly anticipated late-breaking clinical trial results on Tuesday morning at VIVA 17, hosted at the Wynn Las Vegas. Below are highlights […]

Teleflex Inc. (TFX) To Present The Peripheral Intervention Product Portfolio From Its New Subsidiary, Vascular Solutions At The Annual Meeting And Postgraduate Course Of The Cardiovascular And Interventional Radiological Society Of Europe (CIRSE) 2017

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, will showcase the product portfolio recently acquired from its new subsidiary, Vascular Solutions, as well as its Arrow® Hemodialysis, Oncology and Peripheral Intervention Solutions at the CIRSE Congress being held in […]